
Please try another search
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Alan John Barge | 68 | 2015 | Independent Non-Executive Director |
Huw Jones | 66 | 2020 | CEO & Executive Director |
Toni Haenninen | 48 | 2023 | CFO & Director |
Edward Wardle | - | 2025 | Non-Executive Director |
David Alastair Maclaughlin Smith | 59 | 2025 | Independent Non-Executive Chair |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review